Drug Profile
Research programme: single-chain anticancer antibodies - Outlook Therapeutics
Alternative Names: ONS-1010; ONS-1015; ONS-1020; ONS-1025; ONS-1030; ONS-1035; ONS-2010; sc-Fv bi-specificLatest Information Update: 05 Dec 2018
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Oncobiologics; Outlook Therapeutics
- Class Bispecific antibodies; Drug conjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Uterine cancer
Most Recent Events
- 03 Dec 2018 Oncobiologics is now called Outlook Therapeutics
- 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Head-and-neck-cancer in USA (Parenteral)